Delavirdine gains approval as second NNRTI for anti-HIV combination regimens.
D020008:Delavirdine; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D012737:Sex Factors; D014481:United States; D014486:United States Food and Drug Administration
D007211:Indoles; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D020008:Delavirdine